文献速递妇科

抑制AXL可提高曲妥珠单抗在高危子宫内膜癌中的疗效

AXL inhibition improves the therapeutic efficacy of trastuzumab in high-risk endometrial cancer.
PubMed 文献 · Gynecol Oncol · 2025-11-20

研究在高危子宫内膜癌细胞系和荷瘤小鼠中探讨AXL与HER2的相互作用,并评估AXL抑制剂batiraxcept联合曲妥珠单抗的疗效。结果显示两者共定位并相互作用,联合治疗协同降低细胞活力、增殖、侵袭及体内肿瘤负荷,并进一步下调HER2、磷酸化HSP-27、Ki-67、LRG1和LDH-A蛋白。

要点

  • AXL与HER2在高危子宫内膜癌细胞中共定位并相互作用。
  • batiraxcept联合曲妥珠单抗协同降低细胞增殖、侵袭和体内肿瘤负荷。
  • 联合治疗进一步下调HER2、磷酸化HSP-27、Ki-67、LRG1和LDH-A。

核心结论

  • 研究结果支持batiraxcept联合曲妥珠单抗作为侵袭性HER2阳性子宫内膜癌的有前景治疗策略。

研究设计与样本

  • 研究使用三种高危原发性子宫内膜癌细胞系:ARK1和ARK2为子宫浆液性癌,PUC198为3级子宫内膜样腺癌。
  • 在ARK2肿瘤组织和PUC198细胞上进行免疫荧光和邻近连接 assay 评估HER2与AXL的物理相互作用。
  • 细胞分别用溶剂对照、batiraxcept、曲妥珠单抗或两者联合处理,通过集落形成、细胞活力和Matrigel侵袭实验评估增殖和侵袭。
  • 通过反向蛋白阵列检测214种与癌变相关蛋白的表达水平。
  • 治疗也给予注射ARK1和ARK2的小鼠,通过解剖评估肿瘤负荷。

主要发现

  • AXL和HER2在高危子宫内膜癌细胞中共定位并相互作用。
  • batiraxcept加入曲妥珠单抗降低细胞活力,并在体外协同减少细胞增殖和侵袭、在体内协同减少肿瘤负荷。
  • 反向蛋白阵列分析显示,HER2、磷酸化HSP-27、Ki-67、LRG1和LDH-A被曲妥珠单抗下调,联合治疗进一步下调。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Improved treatment options for HER2-expressing tumors are needed, particularly receptor targeted therapies. The receptor tyrosine kinase AXL, which is overexpressed in aggressive endometrial cancers, has been shown to heterodimerize with HER2 and drive resistance to anti-HER2 therapies in other cancers. We investigated this interaction in high-risk endometrial cancer and evaluated whether the AXL inhibitor batiraxcept could enhance the therapeutic effect of trastuzumab. METHODS: We utilized three high-risk primary endometrial cancer cell lines (ARK1 and ARK2, uterine serous carcinoma; PUC198, grade 3 endometrioid adenocarcinoma). Immunofluorescence and proximity ligation assays were performed on an ARK2 tumor, and proximity ligation assay was performed on PUC198 cells to assess the physical interaction of HER2 and AXL. Cells were treated with vehicle, batiraxcept, trastuzumab, or both, and colony formation, cell viability, and Matrigel invasion assays were used to assess cell proliferation and invasion. Expression levels of 214 proteins implicated in carcinogenesis were measured via reverse phase protein array. Treatments were also administered to mice injected with ARK1 and ARK2, and tumor burden evaluated via dissection. RESULTS: Our results demonstrate that AXL and HER2 co-localize and interact in high-risk endometrial cancer cells. We also showed that batiraxcept addition to trastuzumab decreased cell viability and worked synergistically to reduce cell proliferation and invasion in vitro and tumor burden in vivo. Reverse phase protein array analysis revealed that the proteins HER2, phosphorylated HSP-27, Ki-67, LRG1, and LDH-A were downregulated by trastuzumab, and further downregulated by the combination therapy. CONCLUSIONS: Our findings support the combination of batiraxcept and trastuzumab as a promising therapeutic strategy for aggressive HER2+ endometrial cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Tankou J, Ruau S, Walia A, et al. AXL inhibition improves the therapeutic efficacy of trastuzumab in high-risk endometrial cancer. Gynecol Oncol. 2025. PMID: 41270342. doi:10.1016/j.ygyno.2025.11.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。